Digital Pharma's quantum leap: How AI is redefining media measuremen... Welcome to the era where the convergence of quantum computing and artificial intelligence isn't just an advantage, it's the imperative.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.